Ceptaris Therapeutics, Inc.

Developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). The product was approved by the FDA in 2013 and the company was acquired by Actelion in September 2013.

Exited Portfolio Company


Other Companies